Presbyopia is problem related loss of eye sight. A person not able to see a nearby objects due to presbyopia. This problem is natural in aging population. Presbyopia usually becomes noticeable in early age of mid-40s and continues to worsen until around age 65. Presbyopia Solutions or treatment provides compensate for the inability of eyes to focus on nearby objects. The Solution option include wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia.
Highlights from Presbyopia Solutions Market Study
|Unit||Value (USD Million)|
The key Players profiled in the report are Lenz Therapeutics (United States), Visus Therapeutics (United States), Novartis (Switzerland), Atia Vision (United States), Arctic Vision (China), Ocuphire Pharma (United States), LensGen (United States), Orasis (Israel), MAG Optics Inc. (United States) and Presbia PLC (Ireland). Additionally, other players that are part of this comprehensive study are Cellix Bio (India), Refocus Group, Inc. (United States), Tsubota Laboratory (Japan), Eyebright Medical Group (China), ClearSight LLC (United States) and Zinn Labs (United States).
Geographic Breakdown and Segment Analysis
The Global Presbyopia Solutions market presents a comprehensive analysis of the Presbyopia Solutions market by end-user/application (Eye Disease Treatment, Eye Disease Diagnosis and Eye Surgery), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Presbyopia Solutions industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Presbyopia Solutions market
Analyst at AMA have segmented the market study of Global Presbyopia Solutions market by Type, Application and Region.
Influencing Trend:Innovation of Newest Generation Progressive Lenses, Innovation of New Presbyopia Solution Equipment and Rapid Uses of AI in Presbyopia Treatment and Solution
Market Growth Drivers:Rising Cases of Gradual Loss of Eye Sight in Geriatric Populations and Rising Demand for Farsightedness, Nearsightedness and Astigmatism Checkup
Challenges:Lack Of Expertise as Well as Extended Patients Care in Rural Areas, Proper Knowledge Related Presbyopia in Rural Areas and Lack of Proper Specialists Providing Presbyopia Solutions
Restraints:Presbyopia Lens Implants Leads to Glare and Blurring of Eye and High Cost Surgery Option Associated with Presbyopia Solutions
Opportunities:The Worldwide Advancement in Ophthalmology and Continuously Growing Healthcare Infrastructure
Market Developments Activities:On 18 June 2020, Rexahn Pharmaceuticals Inc. agreed to merge with Ocuphire Pharma Inc., a privately held developer of therapies for eye disorders. Farmington Hills, Mich.-based Ocuphire Pharma is developing its lead drug candidate Nyxol eye drops for multiple front-of-the-eye indications, including night vision disturbances, reversal of pharmacologically-induced mydriasis or dilation of the pupil and presbyopia — the gradual loss of the eyes' ability to focus on nearby objects.
On 22 March 2022, Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, announced the launch of the first of two pivotal Phase 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.
The market for Presbyopia Solutions is highly competitive with several global as well as local players in the market. The global players are trying various strategies such as service innovation and using various marketing strategies to gain a higher market share.
Key Target AudiencePresbyopia Solutions Providers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others